Search

Displaying results 3661 - 3670 of 4288 in total
  1. Drug

    AICA ribonucleotide

    go.drugbank.com/drugs/DB01700
    Investigational

    The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity

  2. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  3. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.

  4. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome

  5. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  6. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility

  7. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    It is being developed as an adjunct to chemotherapy.

  8. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

    Synonyms: Immunoglobulin G1 [301-alanine,de-C-terminal-lysine], anti-(human lymphocyte activation gene-3 protein) (human-Mus musculus monoclonal INCAGN02385 γ1-chain), disulfide with human-Mus musculus monoclonal
  9. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.

  10. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.